A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients
Completed · Phase 1 · Has a placebo group
Conditions studied: Healthy Elderly, Parkinson Disease
In brief
This study investigates the safety and tolerability of drug IkT-148009 in healthy elderly volunteers (55 to 70 years old). This first-in-human study is designed in 3 parts. In Part A, healthy participants will take a single, oral dose of IkT-148009 or placebo. Part A participants will be at the study site for approximately 4 days. In Part B, healthy participants will take an oral dose of IkT-148009 once a day for 7 days. Part B participants will be at the study site for approximately 12 days. In Part C, Parkinson\'s patients will take an oral dose of IkT-148009 once a day for 7 days. Part C participants will be at the study site for approximately 12 days.
Key facts
- Study ID
- NCT04350177
- Run by
- ABLi Therapeutics, Inc.
- People needed
- 101
- Starts
- 2021-02-16
- Expected to finish
- 2023-01-30
- Last updated by the study team
- 2025-03-10
Who can join
Age: 55 and older, up to 70. Sex: any. Healthy volunteers: accepted.
Where it is running
- Collaborative Neuroscience Research, LLC — Long Beach, California, United States
- Velocity Clinical Research — Hallandale, Florida, United States
- Quest Research Institute LLC — Farmington Hills, Michigan, United States
- Hassman Research Institute — Marlton, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.